Stocks and Investing
Stocks and Investing
Tue, April 16, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, April 15, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Paul Matteis Maintained (ALNY) at Strong Buy with Increased Target to $116 on, Apr 15th, 2019
Paul Matteis of Stifel, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Increased Target from $110 to $116 on, Apr 15th, 2019.
Paul has made no other calls on ALNY in the last 4 months.
There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 2 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $70 on, Tuesday, April 9th, 2019
- Esther Rajavelu of "UBS" Initiated at Hold on, Wednesday, January 23rd, 2019
This is the rating of the analyst that currently disagrees with Paul
- David Lebovitz of "Morgan Stanley" Upgraded from Hold to Buy on, Tuesday, March 5th, 2019